Rapid Microbiology Testing Market by Product (Instruments (Automated Identification System, PCR, Mass Spectrometer) Reagent, Kits), Method (Growth, Nucleic Acid, Viability), Application (Clinical Diagnosis, Industrial, Research) - Global Forecast to 2029
The rapid microbiology testing market is valued at an estimated USD 5.2 billion in 2024 and is projected to reach USD 8.3 billion by 2029 at a CAGR of 10.1% during the forecast period. There has been a gradual shift from traditional microbiology testing to rapid testing methods in recent years due to the introduction of newer and faster technologies. These technologies eliminate the need for biological amplification of bacteria, making detection quicker and more efficient. Microbial testing has overcome the limitations of long procedural times and exposure to pathogenic strains associated with conventional testing methods. With continuous developments in efficacy, efficiency, accuracy, faster results, and improved functionality, technological advancements in microbiology testing have generated increased interest among clinical laboratories, hospitals, academic institutes, research laboratories, and pharmaceutical & biotechnology companies.
“Reagents & kits segment accounted for the highest growth rate in the rapid microbiology testing market, by product, during the forecast period.”
The rapid microbiology testing market is bifurcated into instruments, reagents & kits, and consumables. The reagents & kits segment in the rapid microbiology testing market is experiencing substantial growth. Major factors driving the growth of this segment include the increasing number of infectious disease diagnostic tests carried out, easy accessibility to a wide range of reagents, and the growing need for more reliable, more specific, and faster detection of microbes in the early stages.
“Nucleic acid-based rapid microbiology testing segment accounted for the highest growth rate in the rapid microbiology testing market, by method, during the forecast period.”
The rapid microbiology testing market is bifurcated into growth-based, cellular component-based, nucleic acid-based, viability-based, and other rapid microbiology testing methods based on method. Nucleic acid-based rapid microbiology testing segment is expected to account for the highest CAGR during the forecast period. The rapid growth of this segment is driven by a combination of technological advancements, greater accuracy, and customization capabilities.
“Asia Pacific: The fastest-growing region rapid microbiology testing market.”
The worldwide market for rapid microbiology testing is categorized into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. Notably, the Asia Pacific region is anticipated to experience the most substantial growth in the forecast period. Emerging economies in this geographical area are observing an upswing in their gross domestic products (GDPs) along with a noteworthy increase in disposable income levels. Consequently, there has been a surge in healthcare expenditure among a larger segment of the population. This trend can be attributed to the sizable patient population and the presence of numerous low-cost device manufacturers in the region.
The break-up of the profile of primary participants in the rapid microbiology testing market:
By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%
By Designation: C-level - 27%, D-level - 18%, and Others - 55%
By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%
The key players in rapid microbiology testing market are bioMérieux SA (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Sartorius AG (Germany), Bruker (US), QuidelOrtho Corporation (US), Charles River Laboratories (US), Neogen Corporation (US), Don Whitley Scientific Limited (UK), Rapid Micro Biosystems, Inc. (US), Gradientech (Sweden), rqmicro AG (Switzerland), Colifast AS (Norway), Serosep Limited (Ireland), Solus PerkinElmer (US), BTNX Inc. (Canada), R-Biopharm AG (Germany), Paragon Genomics, Inc. (US), Kypha Inc. (US), Vivione Biosciences (US), Bactest Ltd. (UK), and CorDx (US).
Research Coverage:
This research report categorizes the rapid microbiology testing market by product (Instruments (automated microbial identification & antimicrobial susceptibility testing systems, mass spectrometers, PCR systems, bioluminescence & fluorescence-based detection systems, cytometers, active air samplers, other instruments), reagents & kits (sterility testing reagents & kits and other reagents & kits), and consumables), by method (Growth-based rapid microbiology testing, cellular component-based rapid microbiology testing, nucleic acid-based rapid microbiology testing, viability-based rapid microbiology testing, and other rapid microbiology testing methods), by application (Clinical disease diagnosis, industrial testing (food & beverage testing, pharmaceutical & biological drug testing, environmental testing, cosmetics & personal care products testing, and other industrial testing applications), and research applications), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the rapid microbiology testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches and recent developments associated with the rapid microbiology testing market. Competitive analysis of upcoming startups in the rapid microbiology testing market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall rapid microbiology testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Increasing incidence of infectious diseases and cancer, technological advancements in rapid microbiology testing, increased funding for R&D and Increased focus on early detection of infectious diseases), opportunities (Growth opportunities in emerging countries), restraints (High capital investments and low cost-benefit ratio and nfavorable regulatory and reimbursement scenario), and challenges (Operational barriers) influencing the growth of the rapid microbiology testing market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the rapid microbiology testing market.
Market Development: Comprehensive information about lucrative markets – the report analyses the rapid microbiology testing market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the rapid microbiology testing market
Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like bioMérieux SA (France), Becton, Dickinson and Company (US), Danaher Corporation (US), Abbott Laboratories (US), and Thermo Fisher Scientific Inc. (US).